When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …

Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

Background The risks after unrelated-donor haemopoietic-cell transplantation with matched
HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 alleles between donor and recipient (10/10 …

To validate current donor selection strategies based on previous international studies, we
retrospectively analyzed 2646 transplantations performed for hematologic malignancies in …

Graft-versus-host disease (GVHD) is a common cause of morbidity and mortality after
allogeneic hematopoietic stem cell transplantation. Systemic findings involving the skin …

Most patients who require allogeneic stem cell transplantation do not have a matched
sibling donor, and many patients do not have a matched unrelated donor. In an effort to …

We hypothesized that the compatibility of each HLA loci between donor and patient induced
divergent transplant-related immunologic responses, which attributed to the individualized …

Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for
various malignant and nonmalignant conditions. 1 The indication for its use has expanded …

The human leukocyte antigen (HLA) class I and class II loci are the most polymorphic genes
in the human genome. Hematopoietic stem cell transplantation requires allele‐level HLA …

For patients with hematologic malignancies and disorders, allogeneic hematopoietic stem
cell transplantation offers a potentially curative treatment option. Many patients develop graft …